- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
FDA approval is identified as a key regulatory catalyst for Transmedics.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approval is identified as a key regulatory catalyst for Transmedics.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Adam Craig reported positive results that could support FDA approval for a treatment.
- FDA approval coincided with Donald Trump's press conference on November 11, 2026.
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- NRx Pharmaceuticals is seeking regulatory approval from the FDA for its drug candidates, NRX-100 and NRX-101.
Coverage
Newest first; wire copies grouped- Simply Wall St.What TransMedics Group (TMDX)'s Upward 2025 Earnings Revisions Mean For Shareholders TransMedics Group recently received multiple upward revisions to its fiscal 2025 earnings estimates from analysts,